M L García de Paredes1, F Del Moral González2, P Martínez Del Prado3, J L Martí Ciriquián4, S Enrech Francés5, M Cobo Dols6, E Esteban González7, A L Ortega Granados8, M Majem Tarruella9, J D Cumplido Burón10, A Gascó Hernández11, E López Miranda12, J P Ciria Santos13, F J de Castro Carpeño14. 1. Department of Oncology, Hospital Ramón y Cajal, Madrid. Electronic address: mgdppds@yahoo.es. 2. Department of Oncology, Hospital Perpetuo Socorro, Alicante. 3. Department of Oncology, Hospital de Basurto, Vizcaya. 4. Department of Oncology, Hospital General de Alicante, Alicante. 5. Department of Oncology, Hospital Universitario de Getafe, Madrid. 6. Department of Oncology, Complejo Hospitalario Regional Carlos Haya, Málaga, Spain. 7. Department of Oncology, Hospital Universitario Central de Asturias, Asturias. 8. Department of Oncology, Complejo Hospitalario de Jaén, Jaén. 9. Department of Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona. 10. Department of Oncology, Hospital Torrevieja Salud, Alicante. 11. Department of Oncology, Hospital Plató, Barcelona. 12. Department of Oncology, Hospital Universitario de Móstoles, Madrid. 13. Department of Radio-Oncology, Hospital Donostia, Guipúzcoa. 14. Department of Oncology, Hospital Universitario La Paz, Madrid, Spain.
Abstract
BACKGROUND: Thirty percent to ninety percent of cancer patients suffer from pain, including neuropathic pain (NP), which results in great burden for cancer patients. Thus, it was of great interest to determine NP prevalence in cancer patients in Spain, to raise awareness of the condition, and aiming to improve management of cancer NP. PATIENTS AND METHODS: A 1-month follow-up prospective epidemiological multicenter study was conducted to assess prevalence and management of NP in Spanish oncologic units. The first 10 cancer patients at each unit diagnosed with NP by the validated Douleur Neuropathique 4 questionnaire (DN4) were recruited. RESULTS: Of 8615 screened patients, 2567 (30%) suffered from pain. From these, 33% had NP according to investigators and 19% according to DN4 test. Three hundred and sixty-six patients (mean age 62.6 years; 61.2% male) were recruited. Pain decrease at 1 month was greater in patients with metastases (P<0.01) and depended on treatment (P<0.05), with 'oxycodone' showing 50.4% pain relief. CONCLUSIONS: NP prevalence in cancer pain is 33%. DN4 reports only about half the cancer NP cases diagnosed by clinicians. Pharmaceutical treatment of cancer pain, including NP, has a greater effect in patients with metastases and seems to depend on the specific treatment used.
BACKGROUND: Thirty percent to ninety percent of cancerpatients suffer from pain, including neuropathic pain (NP), which results in great burden for cancerpatients. Thus, it was of great interest to determine NP prevalence in cancerpatients in Spain, to raise awareness of the condition, and aiming to improve management of cancer NP. PATIENTS AND METHODS: A 1-month follow-up prospective epidemiological multicenter study was conducted to assess prevalence and management of NP in Spanish oncologic units. The first 10 cancerpatients at each unit diagnosed with NP by the validated Douleur Neuropathique 4 questionnaire (DN4) were recruited. RESULTS: Of 8615 screened patients, 2567 (30%) suffered from pain. From these, 33% had NP according to investigators and 19% according to DN4 test. Three hundred and sixty-six patients (mean age 62.6 years; 61.2% male) were recruited. Pain decrease at 1 month was greater in patients with metastases (P<0.01) and depended on treatment (P<0.05), with 'oxycodone' showing 50.4% pain relief. CONCLUSIONS: NP prevalence in cancer pain is 33%. DN4 reports only about half the cancer NP cases diagnosed by clinicians. Pharmaceutical treatment of cancer pain, including NP, has a greater effect in patients with metastases and seems to depend on the specific treatment used.
Authors: Sang Hui Chu; Young Joo Lee; Eon Sook Lee; Yimin Geng; Xin Shelley Wang; Charles S Cleeland Journal: Support Care Cancer Date: 2014-09-26 Impact factor: 3.603
Authors: Juan Antonio García García; Patricia Hernández-Puiggròs; Javier Tesedo Nieto; María Pilar Acín Lázaro; Alfredo Carrera González; Miguel José Arranz Soler; Sergio Maldonado Vega Journal: Pain Res Treat Date: 2016-07-19